SynthesisFrontiers in neuroscience2025
Effectiveness and safety of magnetic resonance-guided unilateral focused ultrasound subthalamotomy for Parkinson's disease: a systematic review and meta-analysis of prospective studies.
Synthesis in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Magnetic resonance-guided focused ultrasound subthalamotomy for Parkinson's disease: a meta-analysis of effectiveness and safety.Neurosurgical review · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with asymmetric, medication-refractory Parkinson's disease (PD) often continue to experience disabling motor symptoms despite optimized pharmacological management. Magnetic resonance-guided focused ultrasound subthalamotomy (FUS-STN) has recently emerged as a promising, non-invasive alternative for improving motor function. However, its overall clinical efficacy and long-term safety remain the subject of active investigation. Methods: We systematically searched PubMed, Cochrane Library, Embase, Web of Science, and ClinicalTrials.gov from their inception to 30 November 2024. Prospective studies that assessed unilateral FUS-STN in patients with PD were included. Data were pooled using RevMan 5.3 for mean differences (MD) with 95% confidence intervals (CIs). Results: Four prospective studies ( Conclusion: Unilateral FUS-STN may offer symptomatic benefits and a general safety profile in selected patients with asymmetric PD. Future investigations should emphasize large-scale, longitudinal, multicenter, and symptom-specific randomized controlled trials to assess the long-term benefits and risks of unilateral FUS-STN in PD patients. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251002754, identifier PROSPERO (CRD420251002754).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.